Technology | Heart Failure | May 07, 2018

Minnesota Living With Heart Failure Questionnaire Qualified for FDA Medical Device Development Tools Program

FDA rules 21-question assessment is viable method for manufacturers and clinical trial sponsors to determine effectiveness of heart failure treatments

Minnesota Living With Heart Failure Questionnaire Qualified for FDA Medical Device Development Tools Program

The CORolla device from Israel-based CorAssist is one example of new devices being manufactured and tested to treat heart failure. The efficacy of this and other new devices under development can now be assessed with the Minnesota Living With Heart Failure Questionnaire. 

May 7, 2018 — The U.S. Food and Drug Administration (FDA) has qualified the Minnesota Living with Heart Failure Questionnaire from the University of Minnesota as part of the Medical Device Development Tools (MDDT) program. This voluntary program is intended to reduce regulatory burden for medical device developers and FDA reviewers by qualifying tools that can aid in the development and evaluation of medical devices. Tools qualified by the FDA can be used by the medical device industry to support device submissions, which could reduce time and resources involved in product development.

The Minnesota Living with Heart Failure Questionnaire is comprised of 21 self-administered questions designed to measure the adverse effects of heart failure on patients’ lives. The patient receives a brief set of instructions, and then uses a scale from zero to five to indicate how much each dimension of heart failure has affected their life over the previous four weeks. The questionnaire asks patients to rate the following dimensions of quality of life:

1) Physical symptoms and signs of heart failure;

2) Common physical/social functions;

3) Psychosocial and cognitive function; and

4) Overall adverse impact on quality of life.

The questionnaire can be used to determine whether a device is effectively treating or improving patients’ quality of life by reducing the adverse impact of heart failure. The instrument can be used as a secondary endpoint in feasibility and pivotal studies of outpatients with symptomatic (New York Heart Association class II and III) heart failure. The questionnaire may be used by medical device companies and sponsor-investigators in controlled clinical trials designed to test superiority or non-inferiority of medical devices in support of regulatory submissions.

When used within the qualified context of use, manufacturers and sponsors do not have to justify their use of the tool, and FDA review staff can accept the use of the tool without the need to reconfirm its suitability and utility.

FDA qualification of a medical device development tool is different from FDA clearance or approval of a medical device. The type of evidence needed to support qualification is not the type of evidence that is needed to support marketing authorization for a medical device.

More information about the Minnesota Living with Heart Failure Questionnaire, including how to access the tool, is available in the Summary of Evidence and Basis for Qualification. More information about the medical device development tools program is available on the FDA’s Medical Device Development Tools webpage. Additional tools will be added to the webpage once they are qualified.

For more information: www.fda.gov

 

Related Content

The U.S. Food and Drug Administration (FDA) has granted market clearance for AstraZeneca's dapagliflozin (Farxiga) to reduce the risk of hospitalization for heart failure (HF) in adults with type 2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.
Feature | Heart Failure | October 21, 2019 | Dave Fornell, Editor
October 21, 2019 – The U.S.
Research Shows Drug Can Extend Survival Rates for Heart Failure Patients
News | Heart Failure | October 16, 2019
Researchers have shown for the first time in preclinical studies that the drug Aliskiren can delay the progression of...
The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms. #TMVR #TCT2019 #TCT19

The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms.

News | Heart Failure | October 04, 2019
October 4, 2019 – Results of a new economic analysis of the COAPT Trial data found that transcatheter mitral valve re
COAPT Trial three-year data show the MitraClip continued effectiveness in heart failure patients with secondary mitral reguritation. #TCT2019 #TCT19 #mitralclip

COAPT Trial three-year data show the MitraClip continues to show safety and effectiveness in heart failure patients with secondary mitral reguritation.

News | Heart Failure | October 03, 2019
October 3, 2019 – The three-year results from the...
Positive Safety, Efficacy Data Reported on AccuCinch Heart Failure Device
News | Heart Failure | September 27, 2019
Ancora Heart Inc. announced results from an interim analysis of heart failure patients treated in the CorCinch FMR...
Max and Debra Ernst Heart Center Opening at Beaumont Hospital, Royal Oak
News | Heart Failure | September 20, 2019
The new Max and Debra Ernst Heart Center at Beaumont Hospital, Royal Oak, Mich., will open Sept. 30. It is dedicated to...
FDA Grants Fast Track Designation for Farxiga in Heart Failure
News | Heart Failure | September 18, 2019
AstraZeneca announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the...
Corvia Medical and physIQ Partner in Global Phase 3 Heart Failure Device Clinical Trial

The REDUCE LAP HF-II study will combine Corvia Medical's InterAtrial Shunt Device (IASD), pictured here, with physIQ's continuous monitoring platform to evaluate the device's efficacy in patients with heart failure. Image courtesy of Corvia Medical.

News | Heart Failure | September 12, 2019
Corvia Medical has sponsored and is actively enrolling patients in a heart failure (HF) device trial that, in addition...
 Tiny Wearable Cameras May Improve Quality of Life in Heart Failure Patients

Image courtesy of Amazon.com

News | Heart Failure | September 11, 2019
The ever-present devices that seem to track all our moves can be annoying, intrusive or worse, but for heart failure...
PARAGON-HF Misses Endpoint in Preserved Heart Failure
News | Heart Failure | September 11, 2019
The angiotensin neprilysin inhibitor sacubitril/valsartan (Entresto) missed its primary endpoint of reducing total...
Overlay Init